InterMune to Present at Three Healthcare Conferences

BRISBANE, Calif., Sept. 7 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at three upcoming healthcare conferences.  The conferences and presentation schedules are as follows:

  • The 2010 Morgan Stanley Global Healthcare Conference in New York on September 13 at 2:10 p.m. EDT;  
  • The Robert W. Baird 2010 Health Care Conference in New York on September 14 at 2:45 p.m. EDT; and
  • The 5th Annual JMP Securities Healthcare Conference in New York on September 28 at 3 p.m. EDT.

To access a live audio webcast of any of these presentations, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com.  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone for which InterMune has completed the Phase 3 CAPACITY program in patients with IPF.  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).  The hepatology portfolio includes the HCV protease inhibitor compound danoprevir (also known as RG7227 or ITMN-191, partnered with Roche) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

SOURCE InterMune, Inc.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.